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MATERIALS AND METHODS
Adult male mice (C57 Black/6J) were obtained from Harlan Laboratory. The University of Cincinnati Animal Care and Use Committee approved the use of mice in these experiments.
Chemicals. BMS was a gift from Bristol-Myers Squibb. DE, wortmannin (WTN), and 5-hydroxydecanoic acid (5-HD) were purchased from Sigma Chemical. The kit for Western blot analysis of phosphorylated and total Akt was purchased from Cell Signaling Technology. DE and WTN were dissolved in DMSO before being added into the perfusion buffer. The final concentration of DMSO was Ͻ0.1%. Other reagents were dissolved in PBS. DMSO alone in this concentration has no effects on hemodynamics (25).
Heart preparation for Langendorff perfusion. Mice weighing 25-30 g were anesthetized with pentobarbital sodium (40 mg/kg ip) and heparinized (5,000 U/kg) to protect the heart against microthrombi. The chest was opened at the sternum, and the heart was quickly removed and cannulated with a 20-gauge phalanged stainless steel cannula. The heart was perfused on a noncirculating Langendorff apparatus with Krebs-Henseleit (KH) buffer, pH 7.4, containing (in mmol/l) 118 NaCl, 4.7 KCl, 1.2 MgSO 4, 1.2 KH2PO4, 2.5 CaCl2, 25 NaHCO3, and 11 glucose (1, 26). The buffer was saturated with 95% O2-5% CO2 at 37°C for 25 min. Heart was perfused at a constant pressure of 80 mmHg. A homemade water-filled balloon was inserted into the left ventricle through the left atrium and was adjusted to a left ventricular end-diastolic pressure (LVEDP) of 5-8 mmHg during initial equilibration. Thereafter, the balloon volume was not changed. However, it is also possible that with constant balloon volume, hearts may suffer some phenomenon of no reflow. The distal end of the catheter was connected to a Digi-Med heart performance analyzer (model 210, version 1.01, Micro-Med) by way of a pressure transducer (Case, Lakewood, CO). Heart was paced at 350 beats/min, except during ischemia. Pacing was reinitiated after 3 min of reperfusion for 120 min in all groups. At the end of the equilibration periods, hearts exhibiting systolic pressure Ͻ75 mmHg were discarded from the study. The index of myocardial function was determined as previously described (25).
Experimental protocol. The experimental protocol is summarized in Fig. 1 . A total of 216 male adult mice were used in this study. Four hearts from each group were used to examine phosphorylation of cytosolic Akt by Western blot analysis. Twenty-four animals from each group were used to measure mitochondrial Akt. Animals were randomized into six groups as follows (in each group, eight animals were used to obtain hemodynamic data): 1) ischemic control, with no pharmacological treatment except 0.9% normal saline; 2) BMStreated group; 3) DE-treated group; 4) BMS ϩ WTN-treated group; 5) BMS ϩ 5-HD-treated group; and 6) WTN-treated group. WTN (15 g/kg) was given 15 min before preconditioning with or without BMS and 15 min before the heart was isolated (half-life of WTN is 2 h). All animals were given drugs intraperitoneally for 20 h before their hearts were subjected to ischemia-reperfusion. After equilibration of 25 min, ischemia was induced by shutting off perfusion buffer for 40 min, followed by 120 min of reperfusion.
Measurement of lactate dehydrogenase. Lactate dehydrogenase (LDH), an indicator of myocardial tissue injury, was determined in the coronary effluent by a coupled enzyme-spectrometric technique (DU Series 500 spectrophotometer, Beckman Instruments), using LDH assay kits (MBL) (25). LDH was measured at 3, 5, 10, 20, and 30 min of reperfusion. The accumulated amount was obtained by integrating the area underneath the individual time course curve for 30 min of reperfusion (26) (Fig. 2D) .
Protein extraction for cytosolic Akt Western blot analysis. All pretreated hearts were taken out in the morning to minimize the effects of insulin. Later, they were weighed and immediately immersed in liquid nitrogen and then stored at Ϫ70°C until use. Each heart tissue sample was homogenized for six bursts of 15 s each at 4°C with a Polytron PT homogenizer (Germany) with the use of lysis buffer containing (in mM) 0.1 NaCl, 10 Tris (pH ϭ 7.6), 1 EDTA, 2 Na pyrophosphate, 2 NaF, 2 ␤-glycerophosphate, 0.5 AEBSF, and a cocktail protease inhibitor tablet as described by Kis and colleagues (15a) . After sonication for 5 s, tissue lysate was centrifuged at 14,000 rpm for 5 min at 4°C. Sonication and centrifugation were repeated again, as previously described, before the supernatant was stored at Ϫ70°C for further analysis. Protein content was determined with bovine serum albumin protein assay reagent kit (Pierce).
Isolation of mitochondria. All steps in the isolation of mitochondria were performed at 4°C in a cold room. After anesthesia was administered, the chest was opened and the heart was quickly removed and perfused on Langendorff apparatus with KH buffer to wash out the blood. Hearts were then transferred into solution containing 180 mM KCl, 10 mM EGTA, and 0.5% bovine serum albumin (KEA). Hearts were dissected to remove atria, large vessels, and fat. Only ventricles were weighed and processed. Ventricular tissue was minced and homogenized in 15 ml KEA solution. KEA medium (10 ml) was then added to the homogenate, which was homogenized again. The homogenate was centrifuged at 2,000 g for 10 min. The supernatant fraction was filtered and centrifuged at 8,000 g for 10 min. The pellet was washed with a solution containing 180 mM KCl and 0.1 mM EGTA (KE) and resuspended. This suspension was centrifuged again at 8,000 g for 10 min. This washing procedure was repeated, and the final mitochondrial pellet was resuspended in a small volume of KE medium. After isolation, the Lowry assay was performed to determine protein concentration for Western blot analysis. The purity of mitochondrial fraction was determined as previously described by Ashraf's laboratory (27) .
Western blot analysis for Akt. Western blot analysis was performed to determine the effect of drugs on total Akt compared with phosphorylated Akt. Equal amounts of protein samples (30 g of protein) were mixed with an equal volume of sample buffer [containing 2% SDS, 100 mM Tris, 0.2% bromophenol blue, 20% glycerol, and 200 mM DTT]. The samples were then boiled for 15 min before loading into each well on 10% polyacrylamide gels (Precast Gels, ISC Bioexpress) and run at 100 V for 2 h. These electrophoresed proteins were transferred from the gel to the nitrocellulose membranes (BioRad). Ponceau's red staining confirmed equal loading and transfer of proteins. The membranes were incubated for 60 min with 5% dry milk and Tris-buffered saline to block nonspecific binding sites. Membranes were incubated at 4°C with anti-total Akt antibody and antiphosphorylated Akt antibodies each in 1:1,000 dilutions on a rocking platform overnight. After being washed thoroughly, blots were incubated with 1:10,000 dilution of horseradish-labeled anti-rabbit IgG for 2 h at room temperature. Later, blots were developed with LumiGlo developing solutions. The amount of total and phosphorylated Akt was quantified by using a computer program.
Terminal dUTP nick-end labeling analysis. Terminal dUTP nickend labeling (TUNEL) assay was performed on 5-m-thick deparaffinized histological sections with a MEBSTAIN Apoptosis Kit II (Medical and Biological Laboratories). TUNEL assay may not be entirely specific for apoptosis but is generally believed to be a good marker for cell apoptosis. The heart tissue was obtained after 2 h of postischemia/reperfusion and processed as described previously by Wang et al. (24) . Sections were stained with diamidino-2-phenylindole to visualize nuclei. Later, they were photographed with an Olympus BX41 microscope (Olympus America, Melville, NY), equipped with a digital camera. Each apoptotic nucleus was carefully checked at high magnification (ϫ1,000) and counted. However, it was difficult to discern cell membrane breaks with light microscopy unless coupled with membrane permeability tracers.
Statistical analysis. All values are expressed as means Ϯ SE. Group comparisons were analyzed by one-way ANOVA (StatView 4.0). All groups were analyzed simultaneously with a Bonferroni/ Dunn test. A difference of P Ͻ 0.05 was considered statistically significant.
RESULTS

Hemodynamics of normal nonischemic hearts.
Preischemic baseline values of left ventricular function in various treatment groups are summarized in Fig. 2 , A-C. The mean values of left ventricular developed pressure (LVDP), LVEDP, and coronary flow (CF) were not significantly different between the groups during equilibration. There was also no significant difference in the body and heart weights between the groups.
Hemodynamic and biochemical effects of ischemia. Heart function was significantly decreased after ischemia. At the end of reperfusion, LVDP and CF were decreased, whereas LVEDP was increased (Fig. 2, A-C) . LDH leakage was also significantly increased on reperfusion in ischemic control group (Fig. 2D) .
Hemodynamic and biochemical effect of BMS and DE on ischemic injury. BMS has been found to be a relatively specific opener of mitoK ATP channels compared with DE, which activates both sarcolemma and mitoK ATP channels (13) . At a lower dose, DE can activate mitochondrial channels only. A significant increase in LVDP and CF was observed in BMS-and DE-treated groups. The effect of BMS on LVDP and CF was greater in DE-treated hearts than in ischemic control hearts (Fig. 2, A-C) . Similarly, LVEDP was decreased more in the BMS-treated hearts compared with ischemic control or DEtreated hearts. In addition, LDH release was greatly reduced in hearts treated with both BMS and DE (Fig. 2D) .
Effect of PI3K blockade on mitoK ATP channel-mediated protection. WTN, a specific inhibitor of the PI3K, was given to test whether it can abolish the protection mediated by mitoK ATP channel openers. WTN treatment caused an increase in LVEDP and reduced CF and LVDP compared with the BMS and DE treatments. LDH leakage was also significantly in- creased compared with the BMS-or DE-treated groups, indicating greater damage to the heart (Fig. 2D) .
Role of Akt in mitoK ATP channel-mediated late preconditioning. To determine the relationship between Akt and mitoK ATP channels, 5-HD, a specific blocker of the mitoK ATP channel, was given to the mice together with BMS 24 h before ischemia. A decrease in LVDP and CF and an increase in LVEDP were observed in 5-HD ϩ BMS-treated hearts compared with BMSor DE-treated hearts (Fig. 2, A-C) . LDH leakage was also significantly increased compared with BMS-or DE-treated hearts (Fig. 2D) .
Phosphorylation of Akt in cytosol by BMS and DE. If BMS and DE can activate PI3K, one would expect activation of Akt, a kinase downstream of PI3K. Phosphorylation of PKB/Akt protein was examined by Western blot analysis 24 h after the drugs were given to the animals. Representative Western blots are illustrated in Fig. 3, A and B . Phosphorylation of Akt was increased in BMS-and DE-treated hearts. PI3K-specific inhibitor WTN caused downregulation of Akt because less phosphorylation was evident in both BMS ϩ WTN or WTN-treated hearts (DE ϩ WTN, data not shown). Similarly, 5-HD, which acts at the mitochondrial level, had no effect on Akt phosphorylation in cytosol because Akt is phosphorylated upstream of mitochondria. This data concluded that mitoK ATP channel openers activated Akt in the cytosol and that only WTN inhibited Akt-phosphorylation here. 5-HD had no effect on Akt phosphorylation in cytosol, because it acts on mitochondrial channels only.
Phosphorylation of Akt in mitochondria by BMS and DE.
Mitochondrial phosphorylation of Akt was examined by Western blot analysis 24 h after the drugs were given to the animals. Representative Western blots of mitochondrial fractions are illustrated in Fig. 3 , C and D. Phosphorylation of Akt was increased in mitochondria isolated from BMS-and DE-treated hearts. PI3K-specific inhibitor WTN caused downregulation of Akt because less phosphorylation was evident in both BMS ϩ WTN-or WTN-treated hearts. Similarly, 5-HD inhibited Akt translocation from cytosol to mitochondria, suggesting that activation of mitochondrial channels plays a critical role in mediating cardioprotective effects of Akt. Despite Akt being phosphorylated in the cytosol upstream of mitochondria, treatment with 5-HD resulted in the inhibition of Akt expression within the mitochondria. These data suggest that mitoK ATP channel openers, such as BMS or DE, activate Akt in the cytosol and that only WTN resulted in inhibition of Aktphosphorylation in cytosol and mitochondria. On the other hand, BMS ϩ 5-HD inhibited phosphorylated Akt translocation to mitochondria.
Time-dependent Akt phosphorylation by BMS. Akt phosphorylation by BMS was time dependent and peaked out at 24 h (Fig. 3E) . The effect of BMS disappeared after 72 and 96 h.
Antiapoptotic effect of BMS and DE on ischemic injury through Akt signaling pathway.
Mice treated with BMS (18 Ϯ 1.2%, P Ͻ 0.05) or DE (22 Ϯ 1.4%, P Ͻ 0.05) had a significant reduction in the number of TUNEL positive nuclei compared with ischemic control mice (47 Ϯ 1.4%, P Ͻ 0.05) shown in Fig. 4 . Apoptosis was also increased in WTN, 5-HD, BMS ϩ WTN, or BMS ϩ 5-HD groups. This data provide further support to the concept that the PI3K-Akt pathway plays a critical role in the protection mediated by the activation of mitoK ATP channels.
DISCUSSION
Akt and mitoK ATP channels in late preconditioning. We have previously demonstrated that activation of mitoK ATP channels elicits strong protection against Ca 2ϩ overload and ischemic injury (23, 25, 26) . These conclusions are well supported by several recent studies (9 -11, 26 ) that document mitoK ATP channel as the end effector in cardioprotection against ischemia during late preconditioning. Grover and colleagues (12) have shown that BMS selectively opens mitoK ATP channels without affecting sarcolemmal channels in vascular smooth muscle, heart, or pancreatic B cells. Moreover BMS is devoid of any vasodilator or proarrhythmic activities (20) and had no effect on cardiac function in the normal heart as demonstrated with Millar's pressure-volume system (data not shown). This study demonstrates that the opening of the mitoK ATP channel by BMS or DE produces delayed cardioprotection 24 h after initial treatment. Because half-life of DE in humans is 72 h (5), it is still not clear how long BMS will last in the plasma of mice. It could also be argued that DE or BMS is trapped in mitochondrial membranes for a longer duration, and thus they induce the late cardiac protective effect. Our results also indicate that BMS elicits stronger cardioprotection than DE. BMS caused less increase in LVEDP and greater improvement in LVDP and CF compared with the DE group (not statistically significant). The participation of Akt/PKB in the opening these mitoK ATP channels is highly attractive. WTN has abrogated this protection when used alone or when WTN and BMS are used together. Our data suggest that Akt phosphorylation in the cytosol causes translocation of phosphorylated-Akt to mitochondria and that this translocation induces its cardioprotection against ischemic-reperfusion injury. Bijur and Jope (3) have also reported similar results, which have suggested that Akt phosphorylation in mitochondria causes activation of various proteins like ATP synthase and glycogen synthase kinase 3-␤ within the mitochondria, and they aid in the reduction of apoptosis. Recently, Nagoshi et al. (18) demonstrated that chronic Akt activation resulted in decreased functional recovery and increased injury after ischemia-reperfusion, which is not in agreement with our current study. However, this disparity might be due to experimental conditions used in the later study in which transgenic mice with cardiac-specific expression of activated Akt were used. Western blot analysis results suggest that blocking Akt translocation to mitochondria prevents Akt from phosphorylating those proteins and results in the loss of its cardiac protection ability, despite the fact that Akt was phosphorylated in the cytosol.
Activation of PI3K/Akt signaling pathway attenuates cell death. We postulated that the PI3K signaling pathway is upstream of mitoK ATP channel, the activation of which results in decreased cardiac cell death and apoptosis. It has been suggested that Akt may mediate its antiapoptotic effects via phosphorylation of BAD (7), induction of Bcl-2 family of proteins (17) , inhibition of cytochrome c release from mitochondria (15) , and phosphorylation and inactivation of the caspase family (8) . There is substantial evidence that Akt activation not only reduces the number of apoptotic cells but also substantially reduced infarct size and even more dramatically improved the cardiac function (16, 22) . Western blot and TUNEL analysis clearly indicate that BMS and DE activated PI3K/Akt pathway and reduced a number of apoptotic nuclei in the myocardium. WTN, a pharmacological inhibitor of PI3K, when given with BMS abolished the protection, and there were no differences between the BMS and the ischemic control groups. When given with BMS, 5-HD had no effect on Akt activation in cytosol but abolished the beneficial effects of mitoK ATP channels. However, given the results obtained by using PI3K inhibitor, these findings provide pharmacological evidence supporting the notion that Akt phosphorylation mediated the opening of mitoK ATP channels, which are downstream targets of Akt.
Activation of Akt only in the cytosol is insufficient to provide cardioprotection unless it is translocated to the mitochondria to phosphorylate various proteins within the mitochondria. Our Western blot analysis data show that activation of mitoK ATP channels results in increased phosphorylation of Akt protein within the mitochondria, leading to increased cell survival by attenuating cell apoptosis. Second, the persistent Akt phosphorylation is due to the persistent activation of the mitoK ATP channel by DE or BMS. (Fig. 4, A-F) . These are important findings, which have strong bearing on the Akt and mitoK ATP channel relationship.
There is sufficient evidence in this study that PI3K/Akt plays a significant role in the reduction of apoptosis through activation of mitoK ATP channels. In the BMS ϩ 5-HD group, an increased number of apoptotic nuclei were seen that support the concept that Akt is upstream of mitoK ATP channels. Despite the fact that Akt is activated in the cytosol, it cannot mediate its antiapoptotic function through mitochondrial K ATP channels unless it is translocated to mitochondria and causes phosphorylation of proteins within the mitochondria.
In conclusion, activation of mitoK ATP channels plays an important role in cardiac protection against ischemia via PI3K and Akt phosphorylation. Our data demonstrate for the first time that translocation of phosphorylated Akt from cytosol to mitochondria during activation of mitoK ATP channels is crucial in the cardiac protection against ischemic-reperfusion injury. 
